Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal Manchanda

India's pharmaceutical sector is shifting beyond traditional generics, with companies pursuing growth in biosimilars, nutraceuticals, and consumer healthcare. Innovation, biosimilars, and contract manufacturing are expected to drive the next phase of profit growth, while complex generics face US FDA approval challenges. Sun Pharma has been highlighted as a preferred domestic investment within the sector.